Proactive Investors
14 Oct 2026, 13:52 UTC · 1h ago
Impact · against what's priced in
The upcoming data presentations for bezisterim in Long COVID and Parkinson's create a short-term volatility catalyst for BioVie. Kodal Minerals' report of strong Q3 performance and production expansion provides a positive update on operational scaling at the Bougouni project.
No priced-in read yet
What the story claims
3 claims · scored −1 bearish … +1 bullish · 1 new · 2 priced in
BioVie will present Phase 2 trial results for bezisterim in Long COVID and Parkinson’s disease at the ANA2026 meeting from October 17 to 20.
Newpublished 14 Oct 2026 for event starting 17 Oct
So whatFull data release within 3 days could trigger significant volatility in BIVI shares based on the specific efficacy percentages revealed.
More positive than 94% of claims this week
Continue reading
5 related stories
The presentation of full Phase 2 data for bezisterim in Long COVID and Parkinson's disease at the ANA2026 meeting introduces an imminent catalyst for price movement based on specific efficacy percentages.
Read from the article alone
No priced-in read yet
The company reported strong third-quarter performance and increased export volumes, alongside plans to expand production at the Bougouni lithium project.
Read from the article alone
Scored by the NIS engine · methodology.
Search tags
SUNRISE-PD Phase 2 trial of 57 early-stage Parkinson's patients showed bezisterim outperformed placebo in daily functioning, motor, and non-motor symptoms.
Priced inarticle references 'topline results' as existing knowledge
So whatPositive Phase 2 results for a 57-patient cohort typically precede a much larger, costlier Phase 3 trial requirement for FDA approval.
More positive than 80% of claims this week
The ADDRESS-LC trial enrolled approximately 200 patients to evaluate bezisterim's effect on Long COVID symptoms like brain fog and fatigue.
Priced inno timing evidence of a new result release
More positive than 67% of claims this week
Which stocks this story touches
More positive than 90% of ticker scores this week
The company is presenting positive Phase 2 trial results for bezisterim in Long COVID and Parkinson's disease.
More positive than 84% of ticker scores this week
The CEO reported strong third-quarter performance, rising export volumes, and production expansion plans for the Bougouni project.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Barrons
1h ago
−1.2%
Price is moving against the score
$1.19 vs $1.20 close before publication (Oct 13) · not market-adjusted
BIVI chart →−7.7%
Price is moving against the score
$84.53 vs $91.63 close before publication (Oct 13) · not market-adjusted
KOD chart →
